285 related articles for article (PubMed ID: 29113202)
1. EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Huang JP; Ling K
Oncol Lett; 2017 Nov; 14(5):5735-5742. PubMed ID: 29113202
[TBL] [Abstract][Full Text] [Related]
2. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
[TBL] [Abstract][Full Text] [Related]
3. Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
Deb G; Shankar E; Thakur VS; Ponsky LE; Bodner DR; Fu P; Gupta S
Mol Carcinog; 2019 Jul; 58(7):1194-1207. PubMed ID: 30854739
[TBL] [Abstract][Full Text] [Related]
4. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway.
Chien YC; Liu LC; Ye HY; Wu JY; Yu YL
Am J Cancer Res; 2018; 8(3):422-434. PubMed ID: 29636998
[TBL] [Abstract][Full Text] [Related]
5. Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.
Yang Y; Zhao Y; Liao W; Yang J; Wu L; Zheng Z; Yu Y; Zhou W; Li L; Feng J; Wang H; Zhu WG
Neoplasia; 2009 Apr; 11(4):313-24. PubMed ID: 19308286
[TBL] [Abstract][Full Text] [Related]
6. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
[TBL] [Abstract][Full Text] [Related]
7. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
[TBL] [Abstract][Full Text] [Related]
8. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of Ezh2 methyltransferase by FOXP3: new insight of FOXP3 into chromatin remodeling?
Shen Z; Chen L; Yang X; Zhao Y; Pier E; Zhang X; Yang X; Xiong Y
Biochim Biophys Acta; 2013 Oct; 1833(10):2190-200. PubMed ID: 23688634
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.
Deb G; Thakur VS; Limaye AM; Gupta S
Mol Carcinog; 2015 Jun; 54(6):485-99. PubMed ID: 24481780
[TBL] [Abstract][Full Text] [Related]
12. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
13. EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Katona BW; Liu Y; Ma A; Jin J; Hua X
Cancer Biol Ther; 2014; 15(12):1677-87. PubMed ID: 25535899
[TBL] [Abstract][Full Text] [Related]
14. Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation.
Bamidele AO; Svingen PA; Sagstetter MR; Sarmento OF; Gonzalez M; Braga Neto MB; Kugathasan S; Lomberk G; Urrutia RA; Faubion WA
Cell Mol Gastroenterol Hepatol; 2019; 7(1):55-71. PubMed ID: 30510991
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Yamaguchi J; Sasaki M; Sato Y; Itatsu K; Harada K; Zen Y; Ikeda H; Nimura Y; Nagino M; Nakanuma Y
Cancer Sci; 2010 Feb; 101(2):355-62. PubMed ID: 19860841
[TBL] [Abstract][Full Text] [Related]
16. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Hayden A; Johnson PW; Packham G; Crabb SJ
Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
18. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer.
Gong C; Yao S; Gomes AR; Man EP; Lee HJ; Gong G; Chang S; Kim SB; Fujino K; Kim SW; Park SK; Lee JW; Lee MH; ; Khoo US; Lam EW
Oncogenesis; 2016 Apr; 5(4):e214. PubMed ID: 27043660
[TBL] [Abstract][Full Text] [Related]
20. MiR-340 Inhibits Triple-Negative Breast Cancer Progression by Reversing EZH2 Mediated miRNAs Dysregulated Expressions.
Shi Z; Li Y; Qian X; Hu Y; Liu J; Zhang S; Zhang J
J Cancer; 2017; 8(15):3037-3048. PubMed ID: 28928895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
